Puma Biotechnology | PBYI - الربح قبل الضريبة

سعر السهم
7.78
التغيير اليومي
-0.02 -0.26%
شهريا
29.67%
سنويا
175.89%
Q2 التوقعات
7.57




الربح قبل الضريبة تغيير تاريخ
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amgen USD 3.92B 2.35B 2025-09
Biogen USD 557.3M 186.7M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
Esperion Therapeutics USD 63.67M 95M 2025-12
Exelixis USD 252.69M 275K 2025-12
Gilead Sciences USD 3.64B 1.21B 2025-09
Glaxosmithkline GBP 2.46B 569M 2025-09
Incyte USD 389.94M 92.37M 2025-12
MacroGenics USD -14.93M 31.75M 2025-12
Moderna USD -187M 631M 2025-09
Novartis USD 4.64B 445M 2025-12
Pfizer USD 3.33B 290M 2025-09
PTC Therapeutics USD -139.08M 116.01M 2025-12
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Takeda JPY 133.86B 105.69B 2025-12
TG Therapeutics USD 45.09M 19.18M 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09